Stonepine Capital Management, LLC Y M Abs Therapeutics, Inc. Transaction History
Stonepine Capital Management, LLC
- $102 Billion
- Q2 2025
A detailed history of Stonepine Capital Management, LLC transactions in Y M Abs Therapeutics, Inc. stock. As of the latest transaction made, Stonepine Capital Management, LLC holds 285,300 shares of YMAB stock, worth $2.43 Million. This represents 1.26% of its overall portfolio holdings.
Number of Shares
285,300
Previous 131,160
117.52%
Holding current value
$2.43 Million
Previous $581 Million
121.45%
% of portfolio
1.26%
Previous 0.57%
Shares
2 transactions
Others Institutions Holding YMAB
# of Institutions
97Shares Held
26MCall Options Held
24KPut Options Held
0-
Paradigm Biocapital Advisors LP New York, NY4.24MShares$36.1 Million0.89% of portfolio
-
Acorn Capital Advisors, LLC New York, NY3.42MShares$29.1 Million10.09% of portfolio
-
Black Rock Inc. New York, NY2.94MShares$25 Million0.0% of portfolio
-
Sofinnova Investments, Inc. Menlo Park, CA2.19MShares$18.7 Million0.67% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.94MShares$16.5 Million0.0% of portfolio
About Y-mAbs Therapeutics, Inc.
- Ticker YMAB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,719,500
- Market Cap $372M
- Description
- Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment o...